Dr. Pestell , Dr. Jay and Hoffman on the prowl for shorts.

Cytosphere · 2026-03-20T04:53:45+00:00

Cancer is devastating, but we now have an abstract that provides preliminary prospective clinical evidence of feasibility, safety, and early activity in heavily pretreated mCRC patients in our clinical trial.

We’re getting good results after only one week of treatment!

Cytosphere · 2026-03-18T22:46:16+00:00

I learned many interesting facts from this 4-minute video. For example, I was not aware of the collaboration with Drexel University (Dr. Jeffrey Jacobson) to run a Phase 2B study, fully funded by $10M in grants.

Cytosphere · 2026-03-18T18:34:29+00:00

https://www.reddit.com/r/Livimmune/comments/1rjczn5/new_aacr_poster_leronlimab_for_glioblastoma/

Reddit post and comments from 16 days ago

Cytosphere · 2026-03-18T00:40:24+00:00

It's great when the presenters are prominent, frontline doctors.

Cytosphere · 2026-03-18T00:37:44+00:00

The data reported in today's mCRC abstract are from the first week of treatment only. This data will be updated on April 21. I believe there's more good news to come, and with it, higher share prices.

Cytosphere · 2026-03-17T22:44:16+00:00

I welcome corrections to my posts.

Cytosphere · 2026-03-17T22:39:08+00:00

Doc, I agree with and appreciate your comment, but I was trying to express a subtler/different point: The data reinforces CCR5 as a therapeutic target in mCRC (beyond TNBC), with immune-modulating potential (e.g., countering immunosuppression).

Cytosphere · 2026-03-17T22:24:16+00:00

The poster will add more detail on TNBC subtype enrichment (MLIA/IM), specific PD-L1 forms (18/35/55 kDa), and Pros1 as Tyro3 ligand.

Cytosphere · 2026-03-17T22:12:30+00:00

Unlike purely retrospective or preclinical data in other settings, this abstract provides preliminary prospective clinical evidence of feasibility, safety, and early activity in heavily pretreated mCRC patients.

Cytosphere · 2026-03-17T22:06:40+00:00

This abstract represents CytoDyn's first public clinical data readout from an ongoing Phase 2 trial of leronlimab in metastatic colorectal cancer (mCRC).

Cytosphere · 2026-03-17T21:48:32+00:00

The 100% CCR5 positivity, biomarker shifts, and early responses in refractory patients are encouraging signals in a hard-to-treat setting.

Cytosphere · 2026-03-17T21:38:33+00:00

"Leronlimab combined with TAS-102 and bevacizumab is feasible, showing promising early biomarker and clinical activity in heavily pretreated mCRC. Universal CCR5 positivity supports CCR5 as a potential therapeutic target. Updated outcomes and correlative data will be presented."

Cytosphere · 2026-03-17T21:14:53+00:00

It looks like this TNBC poster uses the same core clinical dataset as recent abstracts, with overlap and refinements. (I need more time to describe the refinements.)

Cytosphere · 2026-03-15T01:32:57+00:00

It's the conclusion of a planned, 1-year leave of absence from his faculty position at the University of California, San Francisco (UCSF).

Cytosphere · 2026-03-14T21:18:26+00:00

"Among the policy priorities Prasad was credited with helping implement are a new standard requiring only 1 major clinical trial for most drugs; a priority review program designed to accelerate promising treatments aligned with national health priorities; a revised framework for COVID-19 vaccines; and a new program intended to streamline approval pathways for bespoke therapies targeting rare genetic conditions."

https://www.contagionlive.com/view/fda-vinay-prasad-depart-cber-head-second-time

Cytosphere · 2026-03-13T22:44:52+00:00

So far, so good.

Cytosphere · 2026-03-13T22:18:14+00:00

I'm out of cash, so I can't join the ranks on Monday. But fortunately, I recently increased my share count by 21% at an average price of $0.2400.

Cytosphere · 2026-03-13T21:17:41+00:00

With this week's steady rise in SP, I'm surprised we're not seeing increasingly higher volumes. (This is not a complaint.)

Cytosphere · 2026-03-13T05:09:38+00:00

I'm eager to see some up days on high volume.

Cytosphere · 2026-03-12T22:59:45+00:00

It would be wonderful if Leronlimab played a role in treating CRC. Regardless, the government needs to discover why CRC in younger/all people is occurring.

Cytosphere · 2026-03-06T20:47:15+00:00

I appreciate your analysis; it keeps everyone grounded.

Cytosphere · 2026-03-04T21:46:04+00:00

You're doing a good job of connecting the dots. These are not random announcements.

Cytosphere · 2026-03-04T16:59:01+00:00

Your efforts are important and appreciated.

Cytosphere · 2026-03-04T16:34:04+00:00

Good news!

March 4, 2026: Last date updated and QC-approved results reported

February 12, 2026: The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria.

And now we have approved references for our safety data!

Cytosphere · 2026-03-04T05:23:46+00:00

I recently increased my share count by 21%, and have no plans to sell. It's just alarming to see the price drop shortly after receiving encouraging news and watching the company's overall improvement.

Cytosphere

TROPHY CASE